Clinical Research, Pharma & Healthcare FinancingBeiGene Ends Ociperlimab Clinical Program Following Futility AnalysisBusiness WireApril 4, 2025April 7, 2025 by Business WireApril 4, 2025April 7, 2025041 BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the...
